Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

Compass Pathways (NASDAQ:CMPS) executives outlined the company’s latest Phase 3 depression data and commercialization preparations during a Needham conference session moderated by biotech analyst Ami ...

In accordance with NASDAQ Listing Rule 5635 (c) (4), the equity awards were approved by the Compensation and Leadership Development Committee of Compass's Board of Directors and were made as a ...

Shares of Compass Pathways (CMPS 3.62%) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression. Can the highly ...

View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...

Compass Pathways has seen its shares slide in a big way this year. The drugmaker, however, has made significant progress on the clinical front in 2021. This clinical-stage biopharma could be a big ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical tre ...

Despite this, the Food and Drug Administration didn’t formally review a psychedelic compound for federal regulation until ...

Compass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of trading, it opened at $23.40 and closed the ...